Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.93

€1.93

-4.020%
-0.08
-4.020%
-

-

 
31.07.26 / Tradegate WKN: A40AEG / Name: Pentixapharm Holding / Stock / ? /
Latest predictions
16.09.25
14.07%
buy
Best running prediction
-
16.09.25
14.07%
buy
Your prediction

Pentixapharm Holding AG Stock

Heavy losses for Pentixapharm Holding AG today as the stock fell by -€0.080 (-4.020%).

Pros and Cons of Pentixapharm Holding AG in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
S********** s********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

EQS-News: Pentixapharm Completes Capital Increase – New Shares Placed in Full
EQS-News: Pentixapharm Completes Capital Increase – New Shares Placed in Full
EQS-News: Pentixapharm Completes Capital Increase – New Shares Placed in Full
EQS-Adhoc: Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today
EQS-Adhoc: Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today
EQS-Adhoc: Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today
EQS-Adhoc: Pentixapharm Holding AG: Rights offering successfully completed, remaining shares available for subscription through private placement
EQS-Adhoc: Pentixapharm Holding AG: Rights offering successfully completed, remaining shares available for subscription through private placement
EQS-Adhoc: Pentixapharm Holding AG: Rights offering successfully completed, remaining shares available for subscription through private placement